List view / Grid view
Researchers have visualised SARS-CoV-2 protein dynamics using in silico methods. In this article, Navodya Roemer explains how a team from the University of Warwick developed a computational strategy that could assist scientists in the production of new treatments and drugs for COVID-19.
Researchers have developed a novel algorithm, “scArches”, that can compare data on single-cell genomics to better understand diseases.
Researchers have been using artificial intelligence to study how the microbiome interacts with the human system to improve vaccine response.
NICEdrug.ch is an open-access database that may help scientists assess potential drugs for a range of diseases more quickly.
Cell Line Development and cell culture process teams, are you geared up to leverage the vast amount of data generated by high-throughput?
Examining existing R&D processes with a consolidated approach enables the stop of disjointed workflows to engage on the digitisation journey.
With a return to the workplace on the horizon for an increasing number of scientists, Richard Goodwin considers how COVID-19 will impact the ways research is conducted. One outcome he posits is the acceleration of the digital transformation that was already occurring in pharmaceutical R&D.
Researches have provided a proof-of-concept that proteomic analysis could be used to identify drivers of aggressive cancers.
A new phenotype-based compound screening technology, called DeepCE, identified 10 compounds that could be repurposed for COVID-19.
NeuroCOVID will be a resource of clinical information and biospecimens from people who experience neurological problems associated with SARS-CoV-2 infection.
The database could save substantial resources for those wanting to do pre-clinical studies of interventions for age-related diseases, said scientists.
Drs Sam Cooper and Michael Briskin of Phenomic AI, discuss how artificial intelligence (AI) is enabling them to target multi-cellular interactions, such as those in the tumour stroma, for drug development.
Anthony Finbow explains how applying microbiome-based evidence to disease modelling will enable researchers to devise more targeted treatments.
The ARRIVE 2.0 guidelines outline what researchers should include in reports to increase reproducibility and reliability for peer-review, and reduce certain ethical concerns surrounding the use of animals in research.
An area where stem cell biology and medicine are combining effectively is the establishment of new cell therapies. However, current therapies are limited to a narrow set of cell types that can be isolated or created and expanded in vitro. Dr Owen Rackham discusses how utilising computational approaches will further…
